Skip to main content
. 2020 Feb 12;34(2):183–196. doi: 10.1007/s40259-020-00406-1

Table 5.

Proportion of ADA-positive patients (PP population)

Baseline n (%) Week 4 n (%) Week 16 n (%) Week 24 n (%) Week 52 n (%)
DRL_RI (N = 82) 3 (3.3) 1 (1.1) 2 (2.3) 4 (4.6) 12 (14.6)
RTX-US (N = 81) 2 (2.2) 0 3 (3.4) 12 (14.0) 22 (27.5)
RTX-EU (N = 79) 0 1 (1.2) 2 (2.4) 7 (8.0) 22 (26.8)

ADA anti-drug antibody, PP per-protocol, RTX-EU MabThera®, RTX-US Rituxan®